<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Iron dextran: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Iron dextran: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Iron dextran: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8574" href="/d/html/8574.html" rel="external">see "Iron dextran: Drug information"</a> and <a class="drug drug_patient" data-topicid="11127" href="/d/html/11127.html" rel="external">see "Iron dextran: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708946"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Anaphylactic-type reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Anaphylactic-type reactions, including fatalities, have followed the parenteral administration of iron dextran injection. Have resuscitation equipment and personnel trained in the detection and treatment of anaphylactic-type reactions readily available during iron dextran administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Administer a test dose of iron dextran prior to the first therapeutic dose. If no signs or symptoms of anaphylactic-type reactions follow the test dose, administer the full therapeutic iron dextran dose. During all iron dextran administrations, observe for signs or symptoms of anaphylactic-type reactions. Fatal reactions have been reported following the test dose of iron dextran injection. Fatal reactions have also occurred in situations where the test dose was tolerated.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients with a history of drug allergy or multiple drug allergies may be at increased risk of anaphylactic-type reactions to iron dextran.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Appropriate use:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use iron dextran only in patients in whom clinical and laboratory investigations have established an iron-deficient state not amenable to oral iron therapy.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F184543"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Infed</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867259"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Dexiron [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1020277"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Iron Salt, Parenteral</span>;</li>
<li>
<span class="list-set-name">Mineral, Parenteral</span></li></ul></div>
<div class="block don drugH1Div" id="F53462478"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note: Multiple forms for parenteral iron exist; close attention must be paid to the specific product when ordering and administering</b>; incorrect selection or substitution of salt one form for another (dextran vs sucrose) without proper dosage adjustment may result in serious over- or underdosing; test doses are recommended before starting therapy. Discontinue oral iron products prior to administering iron dextran.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note</b>
<b>: </b>Iron dextran: 1 mL provides 50 mg elemental iron.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7550fb40-3093-4c4a-b6f9-a129f7bec73b">Anemia of prematurity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anemia of prematurity:</b> Limited data available: INFeD: IV: 0.2 to 1 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7609274','lexi-content-ref-9403642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7609274','lexi-content-ref-9403642'])">Ref</a></span>) or 20 mg/kg/week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9797624']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9797624'])">Ref</a></span>) with epoetin alfa therapy.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F184556"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: Multiple forms for parenteral iron exist; close attention must be paid to the specific product when ordering and administering</b>; incorrect selection or substitution of one salt form for another (dextran vs sucrose) without proper dosage adjustment may result in serious over- or underdosing; test doses are recommended before starting therapy. Discontinue oral iron products prior to administering iron dextran. Dosing presented as both mg and mL; use caution when ordering and dispensing.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Iron dextran: 1 mL provides 50 mg elemental iron.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6f16d9a-fb94-4888-824b-1ec12eb8d352">Iron-deficiency anemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron-deficiency anemia:</b> Infants ≥4 months, Children, and Adolescents: IM, IV:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Test dose:</i> Usual reported range: 10 to 25 mg (0.2 to 0.5 mL) administered 1 hour prior to starting iron dextran therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14634860','lexi-content-ref-15064942']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14634860','lexi-content-ref-15064942'])">Ref</a></span>). The manufacturer suggests a fixed test dose of 25 mg (0.5 mL); however, lower doses and a weight-based approach may be preferable and some centers have used the following (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gura.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gura.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥4 months and &lt;10 kg: 10 mg (0.2 mL).</p>
<p style="text-indent:-2em;margin-left:6em;">Children 10 to 20 kg: 15 mg (0.3 mL).</p>
<p style="text-indent:-2em;margin-left:6em;">Children &gt;20 kg and Adolescents: 25 mg (0.5 mL).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Calculating total replacement dosage of iron dextran: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Dose (mL) = 0.0442 (Hb<sub>n</sub> - Hb<sub>o</sub>) x LBW + (0.26 x LBW).</p>
<p style="text-indent:-2em;margin-left:8em;">LBW = lean body weight in kg. <b>Note:</b> For patients weighing 5 to 15 kg, use actual body weight.</p>
<p style="text-indent:-2em;margin-left:8em;">Hb<sub>n</sub> = desired hemoglobin (g/dL) = 12 g/dL if ≤15 kg or 14.8 g/dL if &gt;15 kg.</p>
<p style="text-indent:-2em;margin-left:8em;">Hb<sub>o</sub> = measured hemoglobin (g/dL).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intermittent dosing for replacement (multiple doses): </i>Calculate total volume of dose (iron dextran 50 mg/mL elemental iron) from previous equation; if total replacement dose is large, may consider dividing total dose and utilizing smaller incremental dosages not to exceed recommended maximum daily dosages for route.</p>
<p style="text-indent:-2em;margin-left:8em;">Usual maximum daily dosage:</p>
<p style="text-indent:-2em;margin-left:10em;">IV: 100 mg (2 mL)/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:10em;">IM:</p>
<p style="text-indent:-2em;margin-left:12em;">Infants ≥4 months and &lt;5 kg: 25 mg (0.5 mL)/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:12em;">Infants ≥4 months and Children 5 to 10 kg: 50 mg (1 mL)/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:12em;">Children &gt;10 kg and Adolescents: 100 mg (2 mL)/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Total dose infusion:</i> Limited data available; optimal regimen not defined: Infants ≥11 months, Children, and Adolescents: Calculate total dose based on previous equation (total dose should not to exceed 1,000 mg/dose) and administer as a single infusion over 1 hour. Dosing based on experience reported in an observational case series of patients in an outpatient hematology clinic with iron deficiency anemia who were not candidates for oral therapy (n=31; ages: 11 months to 18 years); patients were first administered a test dose of 30 mg over 5 minutes; if no reaction after 15 minutes of observation, the total replacement dose (not to exceed 1,000 mg) was administered; adverse reactions were observed and reported as mild and transient; 5 patients discontinued therapy due to adverse reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23832487']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23832487'])">Ref</a></span>). A retrospective study of pediatric and young adult patients with inflammatory bowel disease (n=34; ages: 6.2 to 20.8 years) reported a similar total dose replacement approach; a test dose of 25 mg was reported and a maximum dose of 2,000 mg over 2 hours was used; 11 allergic reactions were reported; 10 of them were observed during the test dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11964953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11964953'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c9e5ec76-bf29-47f7-8e6d-ba42ce784f26">Acute blood loss; iron replacement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute blood loss; iron replacement:</b>
<b>Note: </b>Assumption: 1 mL of normocytic, normochromic red cells = 1 mg elemental iron; Calculate total volume of dose (iron dextran 50 mg/mL elemental iron); if total replacement dose is large, may consider dividing total dose and utilizing smaller incremental dosages not to exceed recommended maximum daily dosages for route.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥4 months, Children, and Adolescents: IM, IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Replacement iron (mg) = Blood loss (mL) x hematocrit (expressed as a decimal fraction).</p>
<p style="text-indent:-2em;margin-left:6em;">Usual maximum daily dosage:</p>
<p style="text-indent:-2em;margin-left:8em;">IV: 100 mg (2 mL)/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">IM:</p>
<p style="text-indent:-2em;margin-left:10em;">Infants ≥4 months &lt;5 kg: 25 mg (0.5 mL)/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:10em;">Children 5 to 10 kg: 50 mg (1 mL)/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:10em;">Children &gt;10 kg and Adolescents: 100 mg (2 mL)/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1622c1dc-14c3-4c46-b6ce-87ac34262b08">Anemia of chronic renal failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anemia of chronic renal failure: Note:</b> Initiation of iron therapy, determination of dose, and duration of therapy should be guided by results of iron status tests combined with the Hb level and the dose of the erythropoietin stimulating agent. See <b>Reference Range</b> for target levels. There is insufficient evidence to recommend IV iron if ferritin level &gt;500 ng/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17720528']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17720528'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Dosing based on the 2000 KDOQI Anemia Guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDOQI.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDOQI.1'])">Ref</a></span>). More recent KDOQI guidelines and the KDIGO guidelines no longer provide specific dosing recommendations or preferred product for intravenous iron supplementation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17720528','lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17720528','lexi-content-ref-KDIGO.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Predialysis or peritoneal dialysis:</i> Infants, Children, and Adolescents: As a single dose repeated as often as clinically indicated: IV:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;10 kg: 125 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">10 to 20 kg: 250 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;20 kg: 500 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hemodialysis:</i> Infants, Children, and Adolescents: Administer during each dialysis for 10 doses total: IV:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;10 kg: 25 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">10 to 20 kg: 50 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;20 kg: 100 mg.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51128321"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Dialysis removal of iron dextran is negligible.</p></div>
<div class="block dohp drugH1Div" id="F51128322"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F184546"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8574" href="/d/html/8574.html" rel="external">see "Iron dextran: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note</b>: <b>Route of administration: </b>IV iron replacement is preferred over oral replacement in several clinical situations (eg, poor GI absorption, lack of response to or poor tolerability of oral iron, need for rapid repletion, chronic kidney disease, active inflammatory bowel disease, cancer, chronic or extensive blood loss) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Auerbach.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Auerbach.1'])">Ref</a></span>). <b>Dosage expression: </b>Dose is expressed in mg of elemental iron. <b>Test dose: </b>A 25 mg test dose should be administered over ≥30 seconds prior to starting iron dextran therapy; observe for at least 1 hour after test dose prior to administering the remainder of the dose. Some experts administer the test dose over 5 minutes and observe for another 5 to 10 minutes before administering the remainder of the dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Auerbach.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Auerbach.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5aa42e19-cce3-46e3-86fd-af058ff59f63">Cancer/chemotherapy-associated anemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cancer/chemotherapy-associated anemia: IV: Note:</b> Use the iron-deficiency anemia equation for determining a calculated dose, when applicable.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<i>Weekly administration (off-label dosing; INFeD) </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15051778']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15051778'])">Ref</a></span>)<i>:</i></i></p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 1 to 3: Test dose of 25 mg (over 1 to 2 minutes), followed by 75 mg (bolus) once weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 4 and after: 100 mg over 5 minutes once weekly until the calculated dose is reached.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Total dose infusion (off-label dosing; INFeD):</i> Test dose of 25 mg (over 1 to 2 minutes), followed 1 hour later by the balance of the calculated total dose mixed in 500 mL NS and infused at 175 mL/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15051778']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15051778'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="035e1654-7eac-49da-83bd-23b3e0ca305a">Iron-deficiency anemia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron-deficiency anemia, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fixed dose (off-label): </i>
<b>IV:</b> 1 g as a single dose; dilute in 250 mL of NS and administer over 1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21922526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21922526'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Calculated dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>): </i>
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Total dose (mL) = (0.0442 × {desired hemoglobin [g/dL] − observed hemoglobin [g/dL]} × IBW [kg]) + (0.26 × IBW [kg])</p>
<p style="text-indent:-2em;margin-left:6em;">IBW = Ideal body weight in kg; if actual body weight is less than IBW, use actual body weight.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Total required dose is administered as multiple daily doses of ≤2 mL (100 mg) until the full dose is administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>). Some experts recommend the fixed dose option above (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Auerbach.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Auerbach.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f3d5cdd5-6a07-4254-aac7-58f7b7e1c6ff">Iron replacement therapy for blood loss</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron replacement therapy for blood loss:</b>
<b>IM</b> (INFeD, DexIron [Canadian product]), <b>IV</b> (INFeD, DexIron [Canadian product]): Replacement iron (mg) = blood loss (mL) x Hct</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f697f01-66fe-41f3-8c4d-7ff9a727a5e7">Restless legs syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Restless legs syndrome (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use as an alternative to oral iron repletion for patients with malabsorption, intolerance, or lack of response to oral therapy, or need for rapid response to therapy; not recommended for initiation of therapy in patients with serum ferritin &gt;100 mcg/L or transferrin saturation (TSAT) ≥45% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29425576']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29425576'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b> IV:</b> Test dose of 25 mg, followed 1 hour later by 975 mg infused over 1 to 4 hours. Dose may be repeated at least 12 weeks after initial infusion based on initial response, recurrence of restless legs syndrome symptoms, and if serum ferritin &lt;300 mcg/L and TSAT &lt;45% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29425576']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29425576'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990134"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Dialysis removal of iron dextran is negligible.</p></div>
<div class="block doha drugH1Div" id="F50987451"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with extreme caution in patients with severe impairment.</p></div>
<div class="block adr drugH1Div" id="F184514"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, cardiac arrhythmia, chest pain, chest tightness, flushing, hypertension, hypotension, shock, syncope, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, pruritus, skin cyanosis, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, diarrhea, dysgeusia, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukocytosis, lymphadenopathy, purpuric rash</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, type IV hypersensitivity reaction (large IV doses)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sterile abscess</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Atrophy at injection site (IM), fibrosis at injection site (IM), inflammation at injection site, injection site phlebitis (IV), local skin discoloration, local soreness/soreness at injection site (IM), pain at injection site (IM), swelling at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, disorientation, dizziness, headache, loss of consciousness, malaise, numbness, paresthesia, seizure, shivering, unresponsive to stimuli</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, arthritis, asthenia, back pain, exacerbation of arthritis, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, bronchospasm, dyspnea, wheezing</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hypersensitivity: Severe hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F184531"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to iron dextran or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F184511"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity:<b> [US Boxed Warning]: Anaphylactic-type reactions (including fatalities) are associated with parenteral administration of iron dextran. Administer only where resuscitation equipment and personnel trained in detection and treatment of hypersensitivity are available during administration. Administer a test dose prior to the first therapeutic dose. If no signs/symptoms of anaphylactic-type reactions follow the test dose, administer the full therapeutic dose. Monitor for signs/symptoms of hypersensitivity during infusion. Fatal reactions have occurred following a test dose and have occurred in patients who tolerated the test dose. Patients with a history of drug allergy or multiple drug allergies may be at increased risk of anaphylactic-type reactions.</b> The risk of adverse events (including life threatening) was higher with the high-molecular-weight iron dextran formulation (which is no longer commercially available) compared to low-molecular-weight iron dextran (INFeD) (Chertow 2006). Concomitant use of angiotensin-converting enzyme (ACE) inhibitors may also increase the risk of hypersensitivity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reaction: Delayed (1 to 2 days) infusion reaction (including arthralgia, back pain, chills, dizziness, fever, headache, malaise, myalgia, nausea, and/or vomiting) may occur with large doses (eg, total dose infusion) of IV iron dextran; symptoms usually subside within 3 to 4 days.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Allergies/asthma: Use with caution in patients with a significant history of allergies and/or asthma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with pre-existing cardiovascular disease; iron dextran may exacerbate cardiovascular complications.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with extreme caution in patients with serious hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal disease/impairment: In patients with chronic kidney disease (CKD) requiring iron supplementation, the IV route is preferred for hemodialysis patients; either oral iron or IV iron may be used for nondialysis and peritoneal dialysis CKD patients, although an initial 1- to 3-month trial of oral iron therapy is recommended (KDIGO 2012). Avoid use during acute kidney infection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Rheumatoid arthritis: Patients with rheumatoid arthritis may experience acute exacerbation of joint pain and swelling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Anemia in the elderly is often caused by “anemia of chronic disease” or associated with inflammation rather than blood loss. Iron stores are usually normal or increased, with a serum ferritin &gt;50 ng/mL and a decreased total iron binding capacity. IV administration of iron dextran is often preferred over IM in the elderly secondary to a decreased muscle mass and the need for daily injections.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Intramuscular iron dextran use in neonates may be associated with an increased incidence of gram-negative sepsis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: <b>[US Boxed Warning]: Use iron dextran only in patients where clinical and laboratory evidence has established the iron deficient state is not amenable to oral iron therapy.</b> Discontinue oral iron prior to initiating parenteral iron therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Carcinogenicity: Cases of tumor development at prior intramuscular injection sites of iron-carbohydrate complexes have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Iron overload: Exogenous hemosiderosis may result from excess iron stores; patients with refractory anemias and/or hemoglobinopathies may be prone to iron overload with unwarranted iron supplementation.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878503"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Use parenteral iron products with caution in premature neonates; necrotizing enterocolitis has been reported; however, no causal relationship established. </p></div>
<div class="block dosfc drugH1Div" id="F21963476"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Strength of iron dextran complex is expressed as elemental iron.</p></div>
<div class="block foc drugH1Div" id="F184523"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Infed: 50 mg/mL (2 mL)</p></div>
<div class="block geq drugH1Div" id="F184507"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323229"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Infed Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $20.29</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867260"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dexiron: 50 mg/mL ([DSC])</p></div>
<div class="block admp drugH1Div" id="F52613085"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: <b>Note:</b> A test dose should be administered on the first day of therapy; observe the patient for at least 1 hour for hypersensitivity reaction, then the remainder of the day's dose (dose minus the test dose) should be administered. Resuscitation equipment, medication, and trained personnel should be available. An uneventful test dose does not ensure an anaphylactic-type reaction will not occur during administration of the therapeutic dose.</p>
<p style="text-indent:-2em;margin-left:2em;">IM: Use Z-track technique for IM administration (deep into the upper outer quadrant of buttock); alternate buttocks with subsequent injections; administer test dose at same recommended site using the same technique.</p>
<p style="text-indent:-2em;margin-left:2em;">IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Test dose: Typically infuse test dose over at least 30 seconds; in pediatric total dose infusion trials, the test dose (25 to 30 mg) was infused over 5 to 10 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11964953','lexi-content-ref-23832487']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11964953','lexi-content-ref-23832487'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent doses: Doses may be injected undiluted at a rate not to exceed 50 mg/minute; large or total replacement doses may be diluted and infused over 1 to 6 hours at a maximum rate not to exceed 50 mg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15114602']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15114602'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Total dose infusion: Doses of ≤1,000 mg have been administered over 1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11964953','lexi-content-ref-23832487']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11964953','lexi-content-ref-23832487'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F184528"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> A test dose should be administered on the first day of therapy; administer slowly over at least 30 seconds and observe for at least 1 hour for hypersensitivity reaction, then administer the remainder of the day's therapeutic dose (dose minus test dose). Resuscitation equipment, medication, and trained personnel should be available. An uneventful test dose does not ensure an anaphylactic-type reaction will not occur during administration of the therapeutic dose.</p>
<p style="text-indent:-2em;margin-left:2em;">IM (INFeD, DexIron [Canadian product]): Use Z-track technique (displacement of the skin laterally prior to injection); injection should be deep into the upper outer quadrant of buttock; alternate buttocks with subsequent injections. Administer test dose at same recommended site using the same technique.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Test dose should be administered gradually over at least 30 seconds (INFeD) or 5 minutes (DexIron [Canadian product]), or over 1 to 2 minutes (INFeD) for cancer-/chemotherapy-associated anemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15051778']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15051778'])">Ref</a></span>). Subsequent dose(s) may be administered undiluted at a slow gradual rate not to exceed 50 mg/minute (maximum: 100 mg).</p>
<p style="text-indent:-2em;margin-left:4em;">Avoid dilutions with dextrose (increased incidence of local pain and phlebitis).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Total dose infusion (off-label administration):</i> A retrospective analysis in patients with iron deficiency anemia suggests that a total dose infusion of 1,000 mg (diluted in 250 mL of NS) over 1 hour (after an initial test dose) is safe and effective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21922526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21922526'])">Ref</a></span>). Another retrospective analysis in patients with chronic kidney disease and iron deficiency anemia administered the total dose (after the initial test dose) over 4 to 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24845687']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24845687'])">Ref</a></span>). Total dose infusions may be associated with an increased incidence of adverse effects 24 to 48 hours after the infusion. In patients with cancer-/chemotherapy-associated anemia, 1 hour after the test dose, administer the balance of the dose diluted in 500 mL NS and infuse at 175 mL/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15051778']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15051778'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F184536"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block usep drugH1Div" id="F53567400"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of iron deficiency in patients with intolerance to oral iron or unsatisfactory response to oral iron (FDA approved in ages ≥4 months and adults).</p></div>
<div class="block mst drugH1Div" id="F184569"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Iron dextran complex may be confused with ferumoxytol</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299544"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F184516"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimercaprol: May enhance the nephrotoxic effect of Iron Preparations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Iron Preparations may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F6792945"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Iron transfer to the fetus may increase following a maternal infusion of iron dextran (Bauminger 1982; Bingham 1983). Iron transfer to the fetus is regulated by the placenta (BSH [Pavord 2020]; NAS 2020).</p>
<p style="text-indent:0em;margin-top:2em;">There is a risk of adverse maternal reactions (eg, anaphylaxis, hypotension, shock) following use of parenteral iron that may result in fetal bradycardia, especially during the second and third trimesters. Although the risk is rare, immediate treatment for anaphylactoid and/or hypersensitivity reactions should be available (BSH [Pavord 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal iron requirements increase during pregnancy. Untreated iron deficiency and iron deficiency anemia (IDA) in pregnant patients are associated with adverse pregnancy outcomes, including low birth weight, preterm birth, and increased perinatal mortality (ACOG 2021; BSH [Pavord 2020]). Maternal iron deficiency is also associated with fatigue, increased risk of postpartum depression, and possibly postpartum hemorrhage (BSH [Pavord 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Oral and parenteral iron are effective at replacing iron stores in pregnant patients (ACOG 2021), Most studies note iron therapy improves maternal hematologic parameters; however, data related to clinical outcomes in the mother and neonate are limited (FIGO 2019; NAS 2020; USPSTF [Siu 2015]). Parenteral iron therapy may be used in pregnant patients who cannot tolerate or respond to oral iron, when iron deficiency occurs later in pregnancy, or when malabsorption is present (ACOG 2021; BSH [Pavord 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Iron dextran has been evaluated for the treatment of IDA in pregnancy (Auerbach 2017a; Darwish 2019; Reveiz 2011; Rogozińska 2021; Wong 2016). However, due to limited safety data in early pregnancy, use of IV iron is generally not started until the second or third trimester (ACOG 2021; BSH [Pavord 2020]; FIGO 2019).</p>
<p style="text-indent:0em;margin-top:2em;">IV iron may be considered for the treatment of restless legs syndrome in pregnant patients with serum ferritin &lt;30 ng/mL who have failed oral iron; use of IV iron should be avoided during the first trimester (Picchietti 2015; Schneider 2015).</p></div>
<div class="block mopp drugH1Div" id="F53567375"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Hematocrit, hemoglobin, reticulocyte count, serum ferritin, transferrin, percent transferrin saturation, TIBC; takes about 4 weeks of treatment to see increased serum iron and ferritin, and decreased TIBC. Serum iron concentrations should be drawn ≥48 hours after last dose (due to rapid increase in values following administration); signs/symptoms of hypersensitivity reactions (during and ≥30 minutes following infusion); hypotension (following infusion). </p></div>
<div class="block rerp drugH1Div" id="F53567233"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Serum iron:</b> All ages: 22 to 184 mcg/dL.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Total iron binding capacity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants: 100 to 400 mcg/dL.</p>
<p style="text-indent:-2em;margin-left:4em;">Children, Adolescents, and Adults: 250 to 400 mcg/dL.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ferritin:</b></p>
<p style="text-indent:-2em;margin-left:4em;">0 to 6 weeks: 0 to 400 ng/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">7 weeks to 1 year: 10 to 95 ng/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">1 to 9 years: 10 to 60 ng/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">10 to 18 years:</p>
<p style="text-indent:-2em;margin-left:6em;">Male: 10 to 300 ng/mL.</p>
<p style="text-indent:-2em;margin-left:6em;">Female: 10 to 70 ng/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic kidney disease (CKD):</b> Targets for iron therapy (KDOQI Guidelines 2007) to maintain Hgb 11 to 12 g/dL:</p>
<p style="text-indent:-2em;margin-left:6em;">Children: Nondialysis CKD, hemodialysis, or peritoneal dialysis: Ferritin: &gt;100 ng/mL and TSAT &gt;20%.</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: Nondialysis (CKD) or peritoneal dialysis: Ferritin: &gt;100 ng/mL and TSAT &gt;20%.</p>
<p style="text-indent:-2em;margin-left:8em;">Hemodialysis: Ferritin &gt;200 ng/mL and TSAT &gt;20% or CHr (content of hemoglobin in reticulocytes) &gt;29 pg/cell.</p></div>
<div class="block pha drugH1Div" id="F184510"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The released iron, from the plasma, eventually replenishes the depleted iron stores in the bone marrow where it is incorporated into hemoglobin</p></div>
<div class="block phk drugH1Div" id="F184530"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Hematologic response to either oral or parenteral iron salts is essentially the same; red blood cell form and color changes within 3 to 10 days</p>
<p style="text-indent:-2em;margin-left:2em;">Maximum effect: Peak reticulocytosis occurs in 5 to 10 days, and hemoglobin values increase within 2 to 4 weeks; serum ferritin peak: 7 to 9 days after IV dose </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">IM: 60% absorbed after 3 days; 90% after 1 to 3 weeks, the balance is slowly absorbed over months  </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">IV: Uptake of iron by the reticuloendothelial system appears to be constant at about 10 to 20 mg/hour </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 48 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine and feces via reticuloendothelial system</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F184533"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Imferon</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cosmofer</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cosmofer</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Fercayl</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ferrum Hausmann</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Cosmofer | Iron dextran co</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cosmofer</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Irondex</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cosmofer | Fercayl</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cosmofer</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cosmofer</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ferrisat</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cosmofer</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cosmofer</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Cosmofer</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Hibiron</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cosmofer</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ferrobalt</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Imferon</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cosmofer</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Adrelamiv | Biohem | Hierro Dextran | Hierro dextrano | Irondex</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cosmofer</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cosmofer</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Iron</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cosmofer | Dextrafer</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cosmofer | Ferron</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cosmofer</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Codiferon 5 | Desman | Imferon</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Imferon | Irondex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29425576">
<a name="29425576"></a>Allen RP, Picchietti DL, Auerbach M, et al; International Restless Legs Syndrome Study Group (IRLSSG). Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. <i>Sleep Med</i>. 2018;41:27-44. doi:10.1016/j.sleep.2017.11.1126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/29425576/pubmed" id="29425576" target="_blank">29425576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34293770">
<a name="34293770"></a>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 233: Anemia in pregnancy. <i>Obstet Gynecol</i>. 2021;138(2):e55-e64. doi:10.1097/AOG.0000000000004477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/34293770/pubmed" id="34293770" target="_blank">34293770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Auerbach.1">
<a name="Auerbach.1"></a>Auerbach M. Treatment of iron deficiency anemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15051778">
<a name="15051778"></a>Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-associated anemia: a multicenter, open-label, randomized trial. <i>J Clin Oncol.</i> 2004;22(7):1301-1307.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/15051778/pubmed" id="15051778" target="_blank">15051778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28739199">
<a name="28739199"></a>Auerbach M, James SE, Nicoletti M, et al. Results of the first American prospective study of intravenous iron in oral iron-intolerant iron-deficient gravidas. <i>Am J Med</i>. 2017a;130(12):1402-1407. doi:10.1016/j.amjmed.2017.06.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/28739199/pubmed" id="28739199" target="_blank">28739199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28371203">
<a name="28371203"></a>Auerbach M, Macdougall I. The available intravenous iron formulations: history, efficacy, and toxicology. <i>Hemodial Int</i>. 2017b;21(suppl 1):S83-S92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/28371203/pubmed" id="28371203" target="_blank">28371203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21922526">
<a name="21922526"></a>Auerbach M, Pappadakis JA, Bahrain H, Auerbach SA, Ballard H, Dahl NV. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. <i>Am J Hematol.</i> 2011;86(10):860-862. doi:10.1002/ajh.22153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/21922526/pubmed" id="21922526" target="_blank">21922526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3361236">
<a name="3361236"></a>Auerbach M, Witt D, Toler W. Clinical Use of the Total Dose Intravenous Infusion of Iron Dextran. <i>J Lab Clin Med</i>. 1988;111(5):566-570.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/3361236/pubmed" id="3361236" target="_blank">3361236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7085894">
<a name="7085894"></a>Bauminger BB, Walters G, Whicher JT, Duke AB. Effect of total dose infusion of iron dextran on the storage iron content of the human placenta. <i>J Clin Pathol</i>. 1982;35(5):502-506. doi:10.1136/jcp.35.5.502<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/7085894/pubmed" id="7085894" target="_blank">7085894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4198298">
<a name="4198298"></a>Benito RP, Guerrero TC. Response to a Single Intravenous Dose Versus Multiple Intramuscular Administration of Iron Dextran Complex: A Comparative Study. <i>Curr Ther Res Clin Exp</i>. 1973;15(7):373-382.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/4198298/pubmed" id="4198298" target="_blank">4198298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6875017">
<a name="6875017"></a>Bingham D, Khalaf MM, Walters G, Whicher JT. Increased transfer of iron to the fetus after total dose infusion of iron dextran during pregnancy. <i>J Clin Pathol</i>. 1983;36(8):907-909. doi:10.1136/jcp.36.8.907<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/6875017/pubmed" id="6875017" target="_blank">6875017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7647482">
<a name="7647482"></a>Burns DL, Mascioli EA, Bistrian BR. Parenteral iron dextran therapy: a review. <i>Nutrition</i>. 1995;11(2):163-168.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/7647482/pubmed" id="7647482" target="_blank">7647482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9797624">
<a name="9797624"></a>Carnielli VP, Da Riol R, Montini G. Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants. <i>Arch Dis Child Fetal Neonatal Ed.</i> 1998;79(1):F44-F48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/9797624/pubmed" id="9797624" target="_blank">9797624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16286429">
<a name="16286429"></a>Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. <i>Nephrol Dial Transplant</i>. 2006;21(2):378-382. doi:10.1093/ndt/gfi253<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/16286429/pubmed" id="16286429" target="_blank">16286429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23333678">
<a name="23333678"></a>Cho YW, Allen RP, Earley CJ. Lower molecular weight intravenous iron dextran for restless legs syndrome. <i>Sleep Med</i>. 2013;14(3):274-277. doi:10.1016/j.sleep.2012.11.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/23333678/pubmed" id="23333678" target="_blank">23333678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21793279">
<a name="21793279"></a>Daniilidis A, Giannoulis C, Pantelis A, Tantanasis T, Dinas K. Total infusion of low molecular weight iron-dextran for treating postpartum anemia. <i>Clin Exp Obstet Gynecol</i>. 2011;38(2):159-161.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/21793279/pubmed" id="21793279" target="_blank">21793279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28901214">
<a name="28901214"></a>Darwish AM, Khalifa EE, Rashad E, Farghally E. Total dose iron dextran infusion versus oral iron for treating iron deficiency anemia in pregnant women: a randomized controlled trial. <i>J Matern Fetal Neonatal Med</i>. 2019;32(3):398-403. doi:10.1080/14767058.2017.1379988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/28901214/pubmed" id="28901214" target="_blank">28901214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dexiron.1">
<a name="Dexiron.1"></a>Dexiron (iron dextran complex) [product monograph]. Richmond Hill, Ontario, Canada: Fresenius Medical Care Canada Inc; February 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10705077">
<a name="10705077"></a>Dorea JG. Iron and copper in human milk. <i>Nutrition</i>. 2000;16(3):209-220. doi:10.1016/s0899-9007(99)00287-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/10705077/pubmed" id="10705077" target="_blank">10705077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24845687">
<a name="24845687"></a>Dossabhoy NR, Turley S, Gascoyne R, Tapolyai M, Sulaiman K. Safety of total dose iron dextran infusion in geriatric patients with chronic kidney disease and iron deficiency anemia. <i>Ren Fail</i>. 2014;36(7):1033-1037.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/24845687/pubmed" id="24845687" target="_blank">24845687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21548016">
<a name="21548016"></a>El-Farrash RA, Ismail EA, Nada AS. Cord blood iron profile and breast milk micronutrients in maternal iron deficiency anemia. <i>Pediatr Blood Cancer</i>. 2012;58(2):233-238. doi:10.1002/pbc.23184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/21548016/pubmed" id="21548016" target="_blank">21548016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9363415">
<a name="9363415"></a>Emmett PM, Rogers IS. Properties of human milk and their relationship with maternal nutrition. <i>Early Hum Dev</i>. 1997;(49)(suppl):S7-S28. doi:10.1016/s0378-3782(97)00051-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/9363415/pubmed" id="9363415" target="_blank">9363415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30710364">
<a name="30710364"></a>FIGO Working Group on Good Clinical Practice in Maternal-Fetal Medicine. Good clinical practice advice: iron deficiency anemia in pregnancy. <i>Int J Gynaecol Obstet</i>. 2019;144(3):322-324. doi:10.1002/ijgo.12740<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/30710364/pubmed" id="30710364" target="_blank">30710364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7609274">
<a name="7609274"></a>Friel JK, Andrews WL, Hall MS, et al. Intravenous Iron Administration to Very-Low-Birth-Weight Newborns Receiving Total and Partial Parenteral Nutrition. <i>JPEN J Parenter Enteral Nutr</i>. 1995;19(2):114-118.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/7609274/pubmed" id="7609274" target="_blank">7609274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27448465">
<a name="27448465"></a>Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. <i>Sleep Med</i>. 2016;21:1-11. doi:10.1016/j.sleep.2016.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/27448465/pubmed" id="27448465" target="_blank">27448465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gura.1">
<a name="Gura.1"></a>Gura K, Chang E, Casey A, Roach E. Parenteral iron therapy in the pediatric patient: a review. <i>ICAN: Infant, Child, &amp; Adolescent Nutrition</i>. 2011;3(3):145-151.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-INFeD.1">
<a name="INFeD.1"></a>INFeD (iron dextran complex) [prescribing information]. Madison, NJ: Allergan USA Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28761350">
<a name="28761350"></a>Iyoke CA, Emegoakor FC, Ezugwu EC, et al. Effect of treatment with single total-dose intravenous iron versus daily oral iron (III)-hydroxide polymaltose on moderate puerperal iron-deficiency anemia. <i>Ther Clin Risk Manag</i>. 2017;13:647-653. doi:10.2147/TCRM.S112227<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/28761350/pubmed" id="28761350" target="_blank">28761350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDOQI.1">
<a name="KDOQI.1"></a>KDOQI. Anemia in Chronic Kidney Disease. http://www.kidney.org/sites/default/files/docs/anemiainckd.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17720528">
<a name="17720528"></a>KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target. <i>Am J Kidney Dis</i>. 2007;50(3):471-530.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/17720528/pubmed" id="17720528" target="_blank">17720528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease. <i>Kidney Inter</i>. 2013;3(suppl):1-150. http://kdigo.org/clinical_practice_guidelines/pdf/KDIGO-Anemia%20GL.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18310187">
<a name="18310187"></a>Kumar A, Rai AK, Basu S, et al. Cord blood and breast milk iron status in maternal anemia. <i>Pediatrics</i>. 2008;121(3):e673-e677. doi:10.1542/peds.2007-1986<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/18310187/pubmed" id="18310187" target="_blank">18310187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2123218">
<a name="2123218"></a>Lipschitz DA. The anemia of chronic disease. <i>J Am Geriatr Soc</i>. 1990;38(11):1258-1264.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/2123218/pubmed" id="2123218" target="_blank">2123218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11964953">
<a name="11964953"></a>Mamula P, Piccoli DA, Peck SN, Markowitz JE, Baldassano RN. Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease. <i>J Pediatr Gastroenterol Nutr</i>. 2002;34(3):286-290.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/11964953/pubmed" id="11964953" target="_blank">11964953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NAS.2020">
<a name="NAS.2020"></a>National Academies of Sciences, Engineering, and Medicine 2020. <i>Nutrition During Pregnancy and Lactation: Exploring New Evidence: Proceedings of a Workshop</i>. The National Academies Press; 2020. https://doi.org/10.17226/25841</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11229970">
<a name="11229970"></a>National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. <i>Am J Kidney Dis</i>. 2001;37(1)(suppl 1):S182-238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/11229970/pubmed" id="11229970" target="_blank">11229970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9403642">
<a name="9403642"></a>Ohls RK, Harcum J, Schibler KR, Christensen RD. The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double-blind, placebo-controlled study. <i>J Pediatr</i>. 1997;131(5):661-665.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/9403642/pubmed" id="9403642" target="_blank">9403642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31578718">
<a name="31578718"></a>Pavord S, Daru J, Prasannan N, Robinson S, Stanworth S, Girling J; BSH Committee. UK guidelines on the management of iron deficiency in pregnancy. <i>Br J Haematol</i>. 2020;188(6):819-830. doi:10.1111/bjh.16221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/31578718/pubmed" id="31578718" target="_blank">31578718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25553600">
<a name="25553600"></a>Picchietti DL, Hensley JG, Bainbridge JL, et al; International Restless Legs Syndrome Study Group (IRLSSG). Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome/Willis-Ekbom disease during pregnancy and lactation. <i>Sleep Med Rev</i>. 2015;22:64-77. doi:10.1016/j.smrv.2014.10.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/25553600/pubmed" id="25553600" target="_blank">25553600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23832487">
<a name="23832487"></a>Plummer ES, Crary SE, McCavit TL, Buchanan GR. Intravenous low molecular weight iron dextran in children with iron deficiency anemia unresponsive to oral iron. <i>Pediatr Blood Cancer</i>. 2013;60(11):1747-1752.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/23832487/pubmed" id="23832487" target="_blank">23832487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21975735">
<a name="21975735"></a>Reveiz L, Gyte GM, Cuervo LG, et al. Treatments for iron-deficiency anaemia in pregnancy. <i>Cochrane Database Syst Rev</i>. 2011;10:CD003094. doi:10.1002/14651858.CD003094.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/21975735/pubmed" id="21975735" target="_blank">21975735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20975064">
<a name="20975064"></a>Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. <i>J Clin Oncol</i>. 2010;28(33):4996-5010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/20975064/pubmed" id="20975064" target="_blank">20975064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17954703">
<a name="17954703"></a>Rizzo JD, Somerfield MR, Hagerty LK, et al. American Society of Hematology/American Society of Clinical Oncology 2007 clinical practice guideline update on the use of epoetin and darbepoetin. <i>Blood</i>. 2008;111(1):25-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/17954703/pubmed" id="17954703" target="_blank">17954703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34171281">
<a name="34171281"></a>Rogozińska E, Daru J, Nicolaides M, et al. Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis. <i>Lancet Haematol</i>. 2021;8(7):e503-e512. doi:10.1016/S2352-3026(21)00137-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/34171281/pubmed" id="34171281" target="_blank">34171281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14634860">
<a name="14634860"></a>Ruiz-Jaramillo Mde L, Guízar-Mendoza JM, Gutiérrez-Navarro Mde J, Dubey-Ortega LA, Amador-Licona N. Intermittent versus maintenance iron therapy in children on hemodialysis: a randomized study. <i>Pediatr Nephrol</i>. 2004;19(1):77-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/14634860/pubmed" id="14634860" target="_blank">14634860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26498233">
<a name="26498233"></a>Schneider J, Krafft A, Manconi M, et al. Open-label study of the efficacy and safety of intravenous ferric carboxymaltose in pregnant women with restless legs syndrome. <i>Sleep Med</i>. 2015;16(11):1342-1347. doi:10.1016/j.sleep.2015.08.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/26498233/pubmed" id="26498233" target="_blank">26498233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Silber.1">
<a name="Silber.1"></a>Silber MH. Treatment of restless legs syndrome and periodic limb movement disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15114602">
<a name="15114602"></a>Silverstein SB, Rodgers GM. Parenteral iron therapy options. <i>Am J Hematol</i>. 2004;76(1):74-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/15114602/pubmed" id="15114602" target="_blank">15114602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344176">
<a name="26344176"></a>Siu AL; US Preventive Services Task Force. Screening for iron deficiency anemia and iron supplementation in pregnant women to improve maternal health and birth outcomes: US Preventive Services Task Force Recommendation Statement. <i>Ann Intern Med</i>. 2015;163(7):529-536. doi:10.7326/M15-1707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/26344176/pubmed" id="26344176" target="_blank">26344176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15042543">
<a name="15042543"></a>Sloand JA, Shelly MA, Feigin A, Bernstein P, Monk RD. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. <i>Am J Kidney Dis</i>. 2004;43(4):663-670. doi:10.1053/j.ajkd.2003.11.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/15042543/pubmed" id="15042543" target="_blank">15042543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15064942">
<a name="15064942"></a>Warady BA, Kausz A, Lerner G, et al. Iron therapy in the pediatric hemodialysis population. <i>Pediatr Nephrol</i>. 2004;19(6):655-661.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/15064942/pubmed" id="15064942" target="_blank">15064942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26971581">
<a name="26971581"></a>Wong L, Smith S, Gilstrop M, et al. Safety and efficacy of rapid (1,000 mg in 1 hr) intravenous iron dextran for treatment of maternal iron deficient anemia of pregnancy. <i>Am J Hematol</i>. 2016;91(6):590-593. doi:10.1002/ajh.24361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/26971581/pubmed" id="26971581" target="_blank">26971581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27583315">
<a name="27583315"></a>World Health Organization (WHO). <i>Guideline: Iron Supplementation in Postpartum Women</i>. World Health Organization; 2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iron-dextran-pediatric-drug-information/abstract-text/27583315/pubmed" id="27583315" target="_blank">27583315</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13057 Version 193.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
